Aspire Biopharma Inks SPAC Deal At $316M Valuation

By Jade Martinez-Pogue · September 3, 2024, 5:25 PM EDT

Aspire Biopharma Inc., advised by Sichenzia Ross Ference Carmel LLP, on Tuesday announced that it will go public through a merger with special purpose acquisition company PowerUp Acquisition Corp., led by...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Recent Articles By Jade

October 29, 2024
Warren Pushes FTC Chair To Probe Oncology Acquisitions
October 08, 2024
Renovus Capital Clinches 4th PE Fund With $875M In Tow
October 07, 2024
Kirkland-Led Shore Capital Lands Almost $2B Across 3 Funds
October 01, 2024
Latham Helps TJC Clinch 2nd Continuation Fund At $2.1B
September 25, 2024
Cancer Detection Biz To Go Public Via $694M SPAC Merger
September 23, 2024
RSV Vaccine Biz Secures $100M For Series B Funding Round
September 20, 2024
Cardinal Health Pays $1.12B For Integrated Oncology Network
September 18, 2024
Organon To Buy Psoriasis Treatment Biz For Up To $1.2B
September 09, 2024
MBX Biosciences Seeks Up To $136M In Upcoming IPO
September 03, 2024
Semnur Pharmaceuticals To Go Public Via $2.5B SPAC Merger